Compare Enveric Biosciences Inc (ENVB) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard High Dividend Yield ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Vanguard High Dividend Yield ETF trades at $158.47 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 14823.5× Enveric Biosciences Inc's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| ENVB | VYM | |
|---|---|---|
Market Cap | $6.80M | $100.80B |
Volume | 64,867 | 908,176 |
Sector | Health | — |
52-Week High | $10.80 | $167.03 |
52-Week Low | $1.27 | $137.47 |
Typical Hold Time | 14 Days | 138 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
VYM trades at $158.56, up 0.7% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD and IDV. Support sits at $156, with resistance at $159-160. Recent news questions its stock selection methodology after holding Intel and Walgreens through dividend cuts.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include sector concentration in dividend-cut-prone stocks and inflation persistence. Opportunities lie in its low expense ratio and broad diversification across nearly 600 holdings for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
